For mood disorders such as depression, PTSD and anxiety, ketamine infusion therapy is generally not covered by insurance. The reason is regulatory rather than clinical: ketamine is considered an off-label treatment for these conditions, and most plans build their coverage policies around approved indications.
That is the short answer, and it is the one most people need. But it is not the whole picture, because several parts of a course of treatment may still be billable, one closely related treatment is covered, and the appeals landscape is not entirely closed. This article works through what is realistically claimable and what is not.
What Off-Label Actually Means
The phrase causes unnecessary alarm, so it is worth being precise. Ketamine is an FDA-approved medication with a long safety record, approved as an anesthetic. Using an approved drug for a different purpose than its labelled indication is both legal and extremely common across medicine, and it is what off-label describes.
What off-label does not mean is unproven or improper. The use of ketamine for depression is supported by a substantial body of research and is practised widely. What it does mean, practically, is that insurers have no approved indication to anchor a coverage policy to, and in the absence of one they generally decline.
The Part That Is Often Covered
Here is where people leave money unclaimed. The infusion may not be covered, but the clinical care surrounding it frequently is.
The initial psychiatric evaluation is a legitimate billable service in its own right. So, in many cases, are follow-up psychiatric appointments, medication management for any other prescriptions you take, and any therapy provided alongside treatment. These are ordinary mental health services and they do not become unbillable simply because ketamine is part of your wider plan.
Whether your particular clinic bills these separately depends on how it is set up. Some practices operate entirely on a self-pay basis for simplicity. Others bill insurance for the psychiatric components and self-pay only for the infusion itself. It is worth asking directly, because the difference over a course of treatment is not trivial.
Esketamine Is a Different Case
One point causes persistent confusion. Esketamine, administered as a nasal spray in a certified clinical setting, holds an FDA-approved indication for treatment-resistant depression. Because an approved indication exists, insurers do have something to build a policy around, and coverage is considerably more common.
That coverage is not automatic. It typically requires documented failure of an adequate number of antidepressant trials, prior authorization, and treatment at a certified site under a risk management programme. But it is a genuinely different position from intravenous ketamine, and for some patients it is the more accessible route for that reason alone. Our comparison of IV ketamine, Spravato and at-home ketamine covers how the options differ clinically as well as financially.
Out-of-Network Reimbursement
Some patients pursue reimbursement by submitting claims themselves after paying the clinic directly. Results vary widely and we would not want to raise expectations unreasonably, but it costs little to attempt.
What helps is documentation. A superbill from the clinic listing the appropriate procedure and diagnosis codes gives a claim a chance that a plain receipt does not. Records of previous treatments that did not work strengthen a case considerably, because they establish the treatment-resistant picture that makes ketamine a reasonable step rather than a first resort. A letter of medical necessity from the prescribing clinician is worth requesting.
Clinics that handle this routinely tend to have a realistic sense of what succeeds with which plans. That experience is worth asking about.
Public Programmes and Special Situations
Coverage rules differ for public programmes, and the answer is not uniform across states or plan types. Our discussion of whether ketamine treatment is covered by Medicaid addresses that question in more detail.
Health savings and flexible spending accounts are worth mentioning here because they are frequently overlooked. Treatment costs paid from these accounts are made with pre-tax money, which effectively reduces the expense without involving your insurer at all. For many patients this is the single most useful thing they do about cost.
How to Find Out Where You Stand
Rather than assuming, it is worth spending twenty minutes establishing the facts for your own plan.
Call the member services number on your insurance card and ask specifically about coverage for intravenous ketamine infusion for depression, and separately about esketamine nasal spray. Asking about them as two different things matters, because the answers are frequently different and a general question about ketamine often gets a general no.
Ask whether an out-of-network benefit exists for mental health services and what the reimbursement rate is. Ask whether the plan requires prior authorization for esketamine and what its criteria are, since those criteria tell you exactly what documentation to start assembling. Write down the name of the person you spoke to and a reference number for the call, because coverage conversations are frequently revisited.
Your clinic can often do a benefits check on your behalf, and practices that treat this as routine will usually be quicker and more accurate than you will be.
Why the Landscape May Change
It is reasonable to ask whether this situation is permanent, and the honest answer is that nobody knows.
Coverage policy tends to follow regulatory approval, and approval follows evidence. The research base for ketamine in mood disorders has grown substantially and continues to. Esketamine already demonstrates that a coverage pathway opens once an indication exists. Whether intravenous ketamine follows depends on developments that are outside any clinic control and are not worth waiting for if you need treatment now.
What we would say is that policies do get revisited, and a denial today is not necessarily a denial in two years. If you pursue treatment self-pay in the meantime, keeping thorough records of what you tried and how you responded is worth doing, both clinically and for any future claim.
If Your Claim Is Denied
A denial is not necessarily the end. Plans have internal appeals processes, and beyond those, most states provide an external review mechanism through an independent body.
Appeals succeed more often when they address the specific reason given for the denial rather than restating the request. If the reason is that the treatment is investigational, the response needs to address that characterisation. If the reason is that alternatives have not been tried, the response needs to document what was tried and what happened. Generic appeals rarely change outcomes.
Planning Around the Reality
For most people seeking ketamine infusions for a mood disorder, the practical position is that this will be a self-pay treatment, with some surrounding care potentially billable and some tax-advantaged options available. Planning on that basis avoids an unpleasant surprise partway through a course.
Our overview of what ketamine infusion therapy costs sets out realistic totals so you can plan across a full course rather than a single session.
A Note on Comparing Clinics on Coverage Claims
One thing worth watching for as you research. A clinic advertising that it accepts insurance is usually referring to the psychiatric services around treatment rather than to the infusions themselves, and that distinction is not always made clearly in marketing.
This is not necessarily misleading, but it can create an expectation that does not survive the first statement. If a practice tells you it works with your insurer, the useful follow-up question is which specific services will be billed to the plan and which you will pay directly. A clear answer to that question is a reasonable indicator of how the practice will communicate with you generally.
Take an Informed Next Step
If you would like help understanding what your particular plan may or may not cover, and what a realistic financial picture looks like for your situation, reach out to the team at Integrated Neurohealth for a careful, personalized evaluation. We would rather be straightforward with you about this at the outset.
Frequently Asked Questions
Is ketamine therapy covered by insurance? Generally not for mood disorders such as depression, PTSD and anxiety, because ketamine is considered an off-label treatment for those conditions. Surrounding psychiatric care may still be billable.
Why is ketamine considered off-label for depression? Ketamine is FDA-approved as an anesthetic rather than as a depression treatment. Using an approved medication for a different purpose is legal and common, but insurers generally set coverage policies around approved indications.
Is esketamine covered when ketamine infusions are not? Frequently yes. Esketamine holds an FDA-approved indication for treatment-resistant depression, so coverage is more common, though it usually requires prior authorization and documented antidepressant failures.
Can I use an HSA or FSA for ketamine treatment? These accounts can commonly be used for treatment costs, which effectively reduces the expense by using pre-tax money. This is one of the most frequently overlooked options available to self-pay patients.
What should I do if my claim is denied? Read the stated reason and respond to it specifically through the plan internal appeal, then through external review if available. A superbill, records of prior treatments and a letter of medical necessity all strengthen an appeal.
This article is for educational purposes and is not a substitute for personalized medical advice. Ketamine therapy should only be pursued under the supervision of qualified healthcare professionals.
